725
Participants
Start Date
January 5, 2023
Primary Completion Date
February 28, 2033
Study Completion Date
February 28, 2033
Kesimpta
Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
RECRUITING
University of California San Diego OTIS, La Jolla
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY